PATENT CLAIM ANALYSIS

Application Number: 15756591
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-06
Patent Classification: ["514", "036000"]

Abstract:
Novel pseudo-trisaccharide aminoglycosides, represented by Formula I, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.

Claim (Index 30):
The method of  claim 28 , wherein said genetic disorder is selected from the group consisting of cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), ataxia-telangiectasia, Hurler syndrome, hemophilia A, hemophilia B, Usher syndrome, Tay-Sachs Becker muscular dystrophy (BMD), Congenital muscular dystrophy (CMD), Factor VII deficiency, Familial atrial fibrillation, Hailey-Hailey disease, McArdle disease, Mucopolysaccharidosis, Nephropathic cystinosis, Polycystic kidney disease, Rett syndrome, Spinal muscular atrophy (SMA), X-linked nephrogenic diabetes insipidus (XNDI) and X-linked retinitis pigmentosa.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 90.0
- Lexical Diversity: 1.42857
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15453990', '14866960', '13885715', '14461477', '10625059']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8247781228576591
- 35 USC 102 Novelty (BERT): 0.515546088305755
- Combined Prediction Score: 0.7938549194024687
- Mean Citation Score: 310.667372
- Max Citation Score: 319.7449
- Similarity Product: 252.7573286346436

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test